4th International conference on phase 1 and early phase clinical trials

March 1-2, 2018 | Hyatt Regency Hong Kong, Tsim Sha Tsui, 18 Hanoi Road, Kowloon, Hong Kong

Overview

Opportunity to meet and interact with globally renowned speakers and experts.

Exchanging ideas on the latest trends on new drug development in various disease areas, in Asia and worldwide.

ICPOEP2018 is a truly global event in clinical research, bringing together professionals from academic institutions, healthcare organizations, pharmaceutical companies, CROs regulatory authorities and others in exchanging insight and wisdom on the latest trends on new drug development. This year, the highlights will be clinical pharmacology, neurology and oncology.

SUPPORT FROM NEW β INNOVATION FOR THE ORGANIZATION OF THIS CONFERENCE IS GRATEFULLY ACKNOWLEDGED

organizer

The University of Hong Kong Clinical Trials Centre (HKU-CTC) is celebrating its 20th anniversary!

HKU-CTC is an academic clinical research organization established under The University of Hong Kong (HKU) in 1998. It has been authorized as the central platform for management and coordination of clinical studies under HKU and its affiliated teaching hospital – Queen Mary Hospital.

Over the years, HKU-CTC has developed into a leading, full-service professional research organization offering one-stop clinical research solutions. HKU-CTC is devoted to partnering with clinical investigators, research organizations and the healthcare industry in advancing human healthcare by promoting, attracting and facilitating clinical studies of various natures, including:

  • investigator-initiated and industry-sponsored clinical studies;
  • interventional and non-interventional clinical studies;
  • clinical studies on various medicinal products such as small-molecule chemical drugs, biopharmaceuticals, medical devices, diagnostics, traditional/proprietary Chinese medicines, herbal medicines and health supplements;
  • phase 1 to 4 clinical trials;
  • clinical pharmacology and bioavailability/bioequivalence trials; and
  • clinical studies on clinical procedures and methods.

Learn more about HKU-CTC: www.hkuctc.com

organizing COMMITTEE

Chair
Professor Karen Lam

Chairman

Clinical Trials Centre,
The University of Hong Kong

Professor Yu-lung Lau

Chief Director

Clinical Trials Centre,
The University of Hong Kong

Professor Bernard Cheung

Medical Director

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Tommy Cheung

Deputy Medical Director
(Clinical Pharmacology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Joanne Chiu

Deputy Medical Director (Oncology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Thomas Yau

Clinical Associate Professor

Department of Medicine,
The University of Hong Kong

Mr. Henry Yau

Managing Director
Honorary Assistant Professor

Clinical Trials Centre,
The University of Hong Kong

  • Chair
    Professor Karen Lam

    Chairman

    Clinical Trials Centre,
    The University of Hong Kong

  • Professor Yu-lung Lau

    Chief Director

    Clinical Trials Centre,
    The University of Hong Kong

  • Professor Bernard Cheung

    Medical Director

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Tommy Cheung

    Deputy Medical Director
    (Clinical Pharmacology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Joanne Chiu

    Deputy Medical Director (Oncology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Thomas Yau

    Clinical Associate Professor

    Department of Medicine,
    The University of Hong Kong

  • Mr. Henry Yau

    Managing Director
    Honorary Assistant Professor

    Clinical Trials Centre,
    The University of Hong Kong

scientific COMMITTEE

Co-Chair
Professor Bernard Cheung

Medical Director

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Co-Chair
Professor Shu-Leong Ho

Henry G Leong Professor of Neurology

Department of Medicine,
The University of Hong Kong

Co-Chair
Dr. Thomas Yau

Clinical Associate Professor

Department of Medicine,
The University of Hong Kong

Dr. Koon-Ho Chan

Clinical Associate Professor

Department of Medicine,
The University of Hong Kong

Dr. Tommy Cheung

Deputy Medical Director
(Clinical Pharmacology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Joanne Chiu

Deputy Medical Director (Oncology)

Phase 1 Clinical Trials Centre,
The University of Hong Kong

Dr. Roland Leung

Associate Consultant

Department of Medicine,
The University of Hong Kong

Mr. Henry Yau

Managing Director
Honorary Assistant Professor

Clinical Trials Centre,
The University of Hong Kong

  • Co-Chair
    Professor Bernard Cheung

    Medical Director

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Co-Chair
    Professor Shu-Leong Ho

    Henry G Leong Professor of Neurology

    Department of Medicine,
    The University of Hong Kong

  • Co-Chair
    Dr. Thomas Yau

    Clinical Associate Professor

    Department of Medicine,
    The University of Hong Kong

  • Dr. Koon-Ho Chan

    Clinical Associate Professor

    Department of Medicine,
    The University of Hong Kong

  • Dr. Tommy Cheung

    Deputy Medical Director
    (Clinical Pharmacology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Joanne Chiu

    Deputy Medical Director (Oncology)

    Phase 1 Clinical Trials Centre,
    The University of Hong Kong

  • Dr. Roland Leung

    Associate Consultant

    Department of Medicine,
    The University of Hong Kong

  • Mr. Henry Yau

    Managing Director
    Honorary Assistant Professor

    Clinical Trials Centre,
    The University of Hong Kong

speakers

tentative program

  • Day One: March 1, 2018 (Thursday)

  • Time Topics & Speakers
  • 09:30 – 10:00 Morning Tea
  • 10:00 – 11:30 Breakthrough in Parkinson’s Disease Research
  • 10:00 – 10:30 Redefining Parkinson's Disease

    Professor Peter Jenner, Emeritus Professor of Pharmacology, NDRG, Faculty of Life Sciences and Medicine, King’s College London, United Kingdom

  • 10:30 – 11:00 Early-Phase Clinical Trials for Parkinson Disease: Clinical Outcomes and Biomarkers

    Professor Peter LeWitt, Professor of Neurology, Wayne State University School of Medicine and Director, Parkinson Disease and Movement Disorders Program, Henry Ford Hospital, Michigan, United States

  • 11:00 – 11:30 Targeting the LRRK2 Protein Kinase for the Treatment of Parkinson’s disease

    Professor Dario Alessi, Director, MRC Protein Phosphorylation & Ubiquitylation Unit, University of Dundee, United Kingdom

  • 11:30 – 13:00 Lunch
  • 13:00 – 15:00 Advancement in Stroke Therapies
  • 13:00 – 13:30 Understanding Stroke-Induced Heart Disease

    Dr. Luciano Sposato, Associate Professor, Department of Clinical Neurological Sciences and Director of Stroke, Dementia and Heart Disease Laboratory, Western University, London, Ontario, Canada

  • 13:30 – 14:00

    Professor Raymond Cheung, Lee Man Chiu Professor in Neuroscience, Division of Neurology, Department of Medicine, The University of Hong Kong

  • 14:00 – 14:30 Genetic Discovery in Stroke – Positioning for Drug Discovery

    Professor Jonathan Rosand, Professor of Neurology, Harvard Medical School / Managing Director, Neuroscience Institute, Massachusetts General Hospital / Associate Member, Broad Institute, Boston, United States

  • 15:00 – 15:30 Coffee Break
  • 15:30 – 16:00 Welcome Address and Opening Remarks
  • 16:00 – 16:45 Dr. Cheng Yu Tung Award Lectures in Drug Development: Gene Silencing Therapy for Neurodegenerative Disease

    Professor Don W. Cleveland, Head, Laboratory of Cell Biology, Ludwig Institute for Cancer Research, Distinguished Professor and Chair, Department of Cellular and Molecular Medicine, University of California at San Diego, United States

  • 16:45 – 17:30 Panel Discussion: Opportunities and Challenges in Novel Drug Development
  • Day Two: March 2, 2018 (Friday)

  • Time Topics & Speakers
  • 09:00 – 10:30 International Trends of Early Drug Development
  • 09:00 – 09:30 TRENDS IN THE DESIGN OF FIRST-IN-HUMAN TRIALS

    Dr. Mario Tanguay, Vice President, Strategic Development, INC Research/inVentiv Health, Montreal, Canada

  • 09:30 – 10:00

    Professor Haiyan Li, Director, Drug Clinical Trial Center, Peking University 3rd Hospital / Vice Director, Peking University, Clinical Research Institute

  • 10:00 – 10:30 Quality Management for Phase 1 Clinical Trials

    Ms. Agnes Chan, Business Process Management Expert, Quality Management, BioResearch Quality & Compliance Janssen, Singapore

  • 10:30 – 11:00 Coffee Break
  • 11:00 – 12:30 Challenges in Phase 1 and Healthy Volunteer Trials
  • 11:00 – 11:30

    Dr. Tommy Cheung, Deputy Medical Director (Clinical Pharmacology), Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China

  • 11:30 – 12:00 Ethics Review of a Phase 1 Clinical Research in a New Technology

    Dr. Xiu-Qin Wang, Director, Research Operating Office, Jiangsu Academy of Clinical and Translational Research

  • 12:30 – 14:00 Lunch
  • 14:00 – 15:30 Advancement in Oncology Treatment Strategies (I)
  • 14:30 – 15:00 Early Development of Immuno-oncology Therapeutics

    Dr. Archie Tse, Executive Director, Clinical Research Oncology, Merck & Co., Inc., United States

  • 15:00 – 15:30 Evolution of Phase 1 Development in Oncology

    Dr. Jeffrey Jackson, Early Asset Development Lead, Integrated Oncology, Bristol-Myers Squibb, New Jersey, United States

  • 15:30 – 16:00 Coffee Break
  • 16:00 – 18:00 Advancement in Oncology Treatment Strategies (II)
  • 17:00 – 17:30 Immuno-Oncology Combinations in Clinical Development

    Professor Lillian Siu, Director of Phase I and Cancer Genomics Program, BMO Chair in Precision Genomics, Princess Margaret Cancer Centre, Toronto, Canada

  • 17:30 – 18:00 Unbiased approaches to identify new targets and combination therapies in CRC

    Professor Lee M. Ellis, Professor of Surgery and Molecular & Cellular Biology, University of Texas MD Anderson Cancer Center, Houston, United States

  • 18:00 – 18:15 Closing

venue

Hyatt Regency HK,
Tsim Sha Tsui,
18 Hanoi Road,
Kowloon, HKSAR, China

Main Conference

Hyatt Regency HK, Tsim Sha Tsui
18 Hanoi Road, Kowloon, HKSAR, China

Participants could enjoy a special rate at conference hotel by making a reservation via the following link:
Click Here

Past Events

icpoep2016

3rd International Conference on
Phase 1 and Early Phase Clinical Trials

Innovative Drug Development For The Future

Visit Website

icpoep2015

2nd International Conference on
Phase 1 and Early Phase Clinical Trials

New Drug for life Tomorrow - in Asia and Worldwide

Visit Website

icpoep2013

1st International Conference on
Phase 1 and Early Phase Clinical Trials

New Drug for life Tomorrow - in Asia and Worldwide

Visit Website
  • icpoep2016

    3rd International Conference on
    Phase 1 and Early Phase Clinical Trials

    Innovative Drug Development For The Future

    Visit Website
  • icpoep2015

    2nd International Conference on
    Phase 1 and Early Phase Clinical Trials

    New Drug for life Tomorrow - in Asia and Worldwide

    Visit Website
  • icpoep2013

    1st International Conference on
    Phase 1 and Early Phase Clinical Trials

    New Drug for life Tomorrow - in Asia and Worldwide

    Visit Website
Background Image

contact

For enquires, please contact the Conference Secretariat Tel: +852 3605-9679 or +852 2255-4665 Email: icpoep2018@hku.hk